The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ therapeutic use
Antineoplastic Agents
/ therapeutic use
Humans
Immunotherapy
Iodine Radioisotopes
/ therapeutic use
Middle Aged
Network Meta-Analysis
Phenylurea Compounds
/ therapeutic use
Protein Kinase Inhibitors
/ therapeutic use
Quinolines
/ therapeutic use
Radiation Tolerance
Sorafenib
/ therapeutic use
Thyroid Neoplasms
/ drug therapy
Antiangiogenic
Molecular biology
Network
Radioiodine-refractory differentiated thyroid carcinoma
TUTHYREF
Target therapy
Journal
Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
10
03
2019
revised:
07
04
2019
accepted:
17
04
2019
pubmed:
16
6
2019
medline:
19
9
2019
entrez:
16
6
2019
Statut:
ppublish
Résumé
Patients with radioiodine-refractory (RAIR) differentiated thyroid carcinoma (DTC) represent a challenging subgroup of DTC because they are at higher risk of cancer-related death. Multidisciplinary discussions can assess the role and the nature of local treatments, but also determine the optimal timing for first-line antiangiogenic therapy as some of these patients can be followed for several months or years without any treatment. In this review, we will examine the definition of RAIR-DTC, the different treatment options and finally some of the most recent cancer research breakthroughs for RAIR-DTC.
Identifiants
pubmed: 31200896
pii: S0007-4551(19)30223-1
doi: 10.1016/j.bulcan.2019.04.012
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Iodine Radioisotopes
0
Phenylurea Compounds
0
Protein Kinase Inhibitors
0
Quinolines
0
Sorafenib
9ZOQ3TZI87
lenvatinib
EE083865G2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
812-819Informations de copyright
Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.